No Price Adjustment
The issue of abandoning the idea of public regulation of prices for cheap drugs from the VED drug list has been under discussion for a long time. But the problem remains. Manufacturers of cheap drugs, who have no right to increase the retail price, suffer losses. But letting them loose to set their own prices is also not appropriate. FAS once suggested that the maximum prices should be adjusted. However, the idea was not supported by the Government of the Russian Federation at the moment. There will be no adjustment of prices for drugs from the vital and essential drug list (VED) supplied at the price below 50 rubles in 2017. All prices will be kept at their level.